Univest
Univest
  • Markets
  • Anupam Rasayan Analyst Review 2027: EBITDA Up 41% as Fluorine Mix Lifts Margins

    • November 19, 2026
    • Posted by: Chaitanya Auti
    • Category: Market
    No Comments
    Anupam Rasayan Analyst Review 2027: EBITDA Up 41% as Fluorine Mix Lifts Margins

    Anupam Rasayan grew Q2 FY27 EBITDA 41% to ₹202.47 crore as margins widened to about 25%, while net profit rose 14% to ₹64.97 crore. We review brokerage views, the fluorination business, the order book, valuation and the risks for 2027.

    read more
  • 3 Custom Synthesis Chemical Stocks With a Strong Future Roadmap: Aarti Industries, Anupam Rasayan India and Tatva Chintan Pharma Chem

    • October 8, 2026
    • Posted by: Ankit Jaiswal
    • Category: Best Stocks
    No Comments
    3 Custom Synthesis Chemical Stocks With a Strong Future Roadmap: Aarti Industries, Anupam Rasayan India and Tatva Chintan Pharma Chem

    Aarti Industries, Anupam Rasayan India and Tatva Chintan Pharma Chem compared on growth, margins, debt and valuation, with the roadmap and risks investors should track.

    read more